本文選題：腦梗死 + 阿托伐他汀�。� 參考：《山東醫(yī)藥》2017年12期

【摘要】：目的探討氯吡格雷聯(lián)合阿托伐他汀或瑞舒伐他汀用于腦梗死二級預(yù)防的效果。方法選取行二級預(yù)防的腦梗死患者150例,隨機分為阿托伐他汀組、瑞舒伐他汀組,每組75例。兩組均給予氯吡格雷治療,阿托伐他汀組加用阿托伐他汀,瑞舒伐他汀組加用瑞舒伐他汀,均連續(xù)給藥24周。兩組于治療前及治療1、12、24周檢測血清TG、TC、LDL-C及血小板聚集率,記錄兩組治療期間心肌酶升高和肝功能損傷發(fā)生率;隨訪1年,記錄腦梗死復(fù)發(fā)率。結(jié)果兩組治療1、12、24周時血清TC、TG、LDL-C水平及血小板聚集率均低于治療前(P均0.05),各時間點比較差異均無統(tǒng)計學(xué)意義(P均0.05)。阿托伐他汀組及瑞舒伐他汀組治療期間心肌酶升高發(fā)生率分別為5.33%、2.67%,肝功能損傷發(fā)生率分別為2.67%、1.33%,組間比較P均0.05。兩組均完成1年隨訪,阿托伐他汀組及瑞舒伐他汀組腦梗死復(fù)發(fā)率分別為10.67%、8.00%,組間比較P0.05。結(jié)論氯吡格雷聯(lián)合阿托伐他汀或瑞舒伐他汀治療腦梗死的效果及安全性均較好,且兩種方法的效果及安全性比較無明顯差異。
[Abstract]:Objective to investigate the effect of clopidogrel combined with Atto vastatin or resuvastatin on the secondary prevention of cerebral infarction. Methods one hundred and fifty patients with secondary cerebral infarction were randomly divided into Atto vastatin group and resuvastatin group with 75 cases in each group. Both groups were treated with clopidogrel, Atto vastatin plus Atto vastatin and resuvastatin plus resuvastatin for 24 weeks. The serum TGV TCU LDL-C and platelet aggregation rate were measured before and 24 weeks after treatment in both groups, and the incidence of myocardial enzymes and liver function injury were recorded during the treatment, and the recurrence rate of cerebral infarction was recorded after 1 year follow up. Results at 24 weeks after treatment, the level of serum TCU TGG LDL-C and platelet aggregation rate in the two groups were lower than those before treatment (P 0.05), and there was no significant difference between the two groups at each time point (P 0.05). The incidence of myocardial enzyme elevation and liver function injury in Atto and rosuvastatin groups were 5.33 and 2.67, respectively, and the incidence of liver function injury was 2.67 and 1.33, respectively (P < 0.05). The recurrence rate of cerebral infarction in Atto vastatin group and resuvastatin group was 10.67 and 8.00, respectively, with a comparison between the two groups (P0.05). Conclusion Clopidogrel combined with Atto vastatin or rosuvastatin is effective and safe in the treatment of cerebral infarction, and there is no significant difference between the two methods.
【作者單位】： 天門市第一人民醫(yī)院;華中科技大學(xué)同濟醫(yī)學(xué)院附屬同濟醫(yī)院;
【分類號】：R743.33

【相似文獻】

相關(guān)期刊論文 前10條

1 劉玉昊;王晶;王旭;邵一兵;許文亮;惠波;武越;;瑞舒伐他汀治療頸動脈粥樣硬化斑塊的臨床研究[J];現(xiàn)代生物醫(yī)學(xué)進展;2012年01期

2 張光裕;田麗娟;;瑞舒伐他汀治療腦梗死合并頸動脈粥樣硬化患者的療效[J];中國循證心血管醫(yī)學(xué)雜志;2012年05期

3 劉吉香;楊文東;;瑞舒伐他汀對原發(fā)性高血壓患者頸動脈粥樣硬化影響及臨床療效觀察[J];實驗與檢驗醫(yī)學(xué);2014年02期

4 丁娜;;瑞舒伐他汀聯(lián)合前列地爾治療短暫性腦缺血發(fā)作臨床觀察[J];中國實用神經(jīng)疾病雜志;2012年19期

5 王波;王海英;甘慧玲;羅利飛;林莉;;瑞舒伐他汀對急性腦梗死患者血漿血管性假血友病因子和血栓調(diào)節(jié)蛋白水平的影響[J];實用藥物與臨床;2014年06期

6 陶濤;趙琴;龐洪波;李雪芹;;瑞舒伐他汀對腦梗死患者血脂和血液流變學(xué)干預(yù)作用研究[J];檢驗醫(yī)學(xué)與臨床;2014年11期

7 張俊華;于明;蘇建華;韓薇;林偉;;瑞舒伐他汀對腦梗死合并頸動脈粥樣硬化患者神經(jīng)功能缺損及血清炎性因子水平的影響[J];臨床神經(jīng)病學(xué)雜志;2014年03期

8 黎羅明;王W，

本文編號：2054641